Welcome to our dedicated page for Viatris Ord Shs news (Ticker: VTRS), a resource for investors and traders seeking the latest updates and insights on Viatris Ord Shs stock.
Viatris Inc. (Nasdaq: VTRS) is a global healthcare company that regularly issues news on its operations, strategy and pipeline across generics, established brands and innovative medicines. This news page aggregates company announcements, press releases and third-party coverage related to VTRS, giving readers a single place to review the latest corporate developments.
Viatris frequently reports on regulatory milestones in its global pipeline. Recent updates include FDA approval of octreotide acetate for injectable suspension as a generic version of Sandostatin LAR Depot, FDA acceptance of a New Drug Application for a low dose estrogen weekly contraceptive patch, FDA clearance of an IND for the MR‑146 gene therapy candidate in neurotrophic keratopathy, and acceptance of a Japanese New Drug Application for pitolisant in obstructive sleep apnea syndrome. The company also announces progress in Japan and the Asia-Pacific region, such as the acquisition of Aculys Pharma and rights to pitolisant and Spydia nasal spray.
Investors can also find financial and corporate news, including quarterly results, updates to financial guidance, capital return actions like dividends and share repurchases, and information on enterprise-wide strategic reviews. Viatris’ participation in major healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference and other sector events, is typically announced through press releases that are reflected in the news flow.
Additional news items may cover business development and collaborations, such as research agreements to develop engineered bacteriophage products for ophthalmic infections, as well as governance updates, board appointments and changes to corporate bylaws. For anyone tracking VTRS, this page offers a concise view of how Viatris communicates its strategy to strengthen its core portfolio, expand innovative brands and optimize its global structure.
Viatris (Nasdaq: VTRS) reported Q4 2025 total revenues of $3.7B and FY2025 total revenues of $14.3B, met or exceeded 2025 guidance across key metrics, and returned over $1B to shareholders. The company completed an enterprise strategic review, expects up to $650M in net cost savings, and provided 2026 guidance while noting multiple upcoming regulatory milestones and an expected workforce reduction of up to 10%.
Key financials: Q4 adjusted EBITDA of $1.003B, Q4 adjusted EPS of $0.57, FY adjusted EBITDA of $4.16B, FY free cash flow of $1.94B, and a FY U.S. GAAP net loss of $(3.51B) reflecting a $2.9B goodwill impairment.
Viatris (Nasdaq: VTRS) announced its 2026 dividend policy of $0.48 per share and declared a quarterly dividend of $0.12 per share. The dividend is payable on March 18, 2026 to shareholders of record as of March 9, 2026.
This marks the sixth consecutive year the company has paid a dividend.
Viatris (Nasdaq: VTRS) announced FDA acceptance of the supplemental New Drug Application for MR-141 (phentolamine ophthalmic solution 0.75%) for presbyopia, with a PDUFA goal date of October 17, 2026. The sNDA is supported by positive Phase 3 VEGA-2 and VEGA-3 results that met primary and all key secondary endpoints with no treatment-related serious adverse events.
Ryzumvi (phentolamine 0.75%) is already approved in the U.S. for pharmacologically-induced mydriasis; the sNDA seeks to expand the indication to include presbyopia. VEGA-3 data will be presented at ASCRS in April and ARVO in May.
Viatris (Nasdaq: VTRS) will report fourth quarter and full year 2025 financial results on February 26, 2026 and will host a live webcast at 8:30 a.m. ET the same day. A replay will be available on the investor website.
Viatris also will host an Investor Event in New York City on March 19, 2026; additional details and pre-registration information will be provided during the February 26 investor call.
Viatris (Nasdaq: VTRS) appointed Matthew J. Maletta as Chief Legal Officer, effective February 9, 2026, with outgoing CLO Brian Roman remaining as advisor through April 1, 2026.
Maletta brings nearly 30 years of legal experience in branded and generic pharmaceuticals, including leadership roles at Endo and Allergan and involvement in a $70 billion Allergan transaction.
Viatris (Nasdaq: VTRS) announced the launch of Inpefa (sotagliflozin) in the United Arab Emirates, the first market within Viatris territories to commercialize the drug, with additional launches planned across multiple countries over the next several years.
Inpefa is the first dual SGLT1/2 inhibitor approved to reduce risk of cardiovascular death, heart failure hospitalization, and urgent heart failure visits. Approval is supported by two Phase 3 trials (SOLOIST-WHF and SCORED; >11,800 patients) showing a 33% reduction in the composite endpoint in SOLOIST-WHF (up to 51% when initiated prior to discharge), 25% reduction in SCORED, and a 23% reduction in MACE, including 32% reduction in MI and 34% reduction in stroke.
Aon (NYSE: AON) launched Resilience Quotient, a data-driven framework that combines Aon's Risk Capital and Human Capital analytics with Gallup World Poll sentiment data (covering 140 countries over 20+ years) to give a portfolio view of risk and resilience.
The tool maps how four megatrends—Trade, Technology, Weather and Workforce—compound risk, offers three case studies (data center growth with a $1.3 trillion 2030 data‑center investment projection, AI workforce transformation, and humanitarian finance for forced migration), and is delivered via a real-time, AI-enabled analytics platform built by Quantum Rise. Aon and Gallup will discuss the work at the World Economic Forum Annual Meeting.
Viatris (Nasdaq: VTRS) appointed Lara Ramsburg as Chief People and Corporate Affairs Officer effective Jan. 8, 2026. The newly combined role will align internal people functions with external corporate affairs to advance culture, stakeholder communication and sustainability priorities. Ramsburg brings more than 25 years of experience and has led Viatris corporate affairs since 2019, previously serving in the Office of the CEO and as Head of Integration. Responsibilities now include global talent, total rewards, employee experience, people solutions and HR business partners.
Viatris (Nasdaq: VTRS) reported four regulatory milestones across its global pipeline on Dec 18, 2025: FDA approval of a generic octreotide acetate injectable suspension (generic Sandostatin LAR Depot); FDA acceptance of an NDA for a low dose estrogen weekly contraceptive patch with a PDUFA date of July 30, 2026; FDA clearance of an IND for MR-146 AAV gene therapy with a planned Phase 1/2 CORVITA trial in H1 2026; and PMDA acceptance of a J-NDA for pitolisant in obstructive sleep apnea syndrome, with a J-NDA for narcolepsy still on track by year-end.
These items advance development and regulatory pathways across generics, women’s health, ophthalmology gene therapy, and sleep-disorder franchises.
Viatris (Nasdaq: VTRS) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 13, 2026. The company's presentation and fireside chat begin at 9:00 a.m. PT / 12:00 p.m. ET. A live webcast will stream at investor.viatris.com, and an archived recording will be available at the same location for a limited time after the event.